NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
1.23
Dollar change
-0.02
Percentage change
-1.60
%
Index- P/E- EPS (ttm)-0.24 Insider Own19.64% Shs Outstand227.22M Perf Week-10.22%
Market Cap279.58M Forward P/E- EPS next Y-0.47 Insider Trans0.00% Shs Float182.66M Perf Month8.85%
Enterprise Value224.44M PEG- EPS next Q-0.18 Inst Own58.35% Short Float6.06% Perf Quarter5.13%
Income-51.24M P/S2.24 EPS this Y-168.69% Inst Trans-0.92% Short Ratio5.76 Perf Half Y45.75%
Sales124.59M P/B- EPS next Y30.71% ROA-18.98% Short Interest11.08M Perf YTD35.97%
Book/sh-0.03 P/C1.08 EPS next 5Y15.97% ROE-500.57% 52W High1.55 -20.65% Perf Year30.95%
Cash/sh1.13 P/FCF- EPS past 3/5Y56.92% 40.29% ROIC-26.18% 52W Low0.66 85.88% Perf 3Y-83.73%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin97.20% Volatility6.44% 7.46% Perf 5Y-90.36%
Dividend TTM- EV/Sales1.80 EPS Y/Y TTM78.54% Oper. Margin-43.96% ATR (14)0.10 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.71 Sales Y/Y TTM- Profit Margin-41.13% RSI (14)48.41 Recom1.44
Dividend Gr. 3/5Y- - Current Ratio5.71 EPS Q/Q13.03% SMA20-4.45% Beta1.87 Target Price7.61
Payout- Debt/Eq- Sales Q/Q- SMA507.27% Rel Volume1.03 Prev Close1.25
Employees145 LT Debt/Eq- EarningsMay 15 AMC SMA20019.94% Avg Volume1.92M Price1.23
IPOFeb 08, 2019 Option/ShortYes / Yes EPS/Sales Surpr.14.48% 143.13% Trades Volume1,975,322 Change-1.60%
Date Action Analyst Rating Change Price Target Change
Jun-25-24Initiated Oppenheimer Outperform $9
Apr-05-24Resumed Wedbush Outperform $4
Jul-27-23Downgrade UBS Buy → Neutral $8 → $1.25
Mar-07-23Downgrade Raymond James Outperform → Mkt Perform
Mar-01-23Initiated Guggenheim Neutral
Dec-07-22Downgrade SMBC Nikko Outperform → Neutral $3
Dec-07-22Downgrade JP Morgan Neutral → Underweight
Dec-07-22Downgrade Barclays Overweight → Equal Weight $18 → $2
Oct-20-22Initiated Goldman Buy $22
Sep-21-22Initiated JP Morgan Neutral $17
Jun-24-25 12:46PM
Jun-16-25 07:31AM
Jun-06-25 05:30PM
May-21-25 07:00AM
May-16-25 09:11AM
03:15AM Loading…
03:15AM
May-15-25 05:15PM
04:09PM
04:01PM
May-14-25 09:45AM
May-12-25 04:01PM
May-07-25 05:30PM
04:01PM
May-02-25 01:21PM
Apr-16-25 09:57AM
09:44AM Loading…
Apr-09-25 09:44AM
Apr-08-25 05:30PM
Mar-27-25 09:45AM
Mar-26-25 01:38PM
Mar-23-25 08:41AM
Mar-13-25 05:10PM
04:06PM
04:01PM
Mar-07-25 05:30PM
Feb-19-25 06:00AM
Feb-07-25 05:30PM
Feb-03-25 07:01AM
Jan-28-25 07:01AM
Jan-07-25 05:30PM
09:19AM
12:00PM Loading…
Dec-26-24 12:00PM
Nov-21-24 12:00PM
Nov-15-24 09:35AM
Nov-14-24 09:35AM
Nov-11-24 04:01PM
Nov-07-24 06:00PM
04:59PM
04:03PM
Oct-31-24 07:00AM
Oct-30-24 07:00AM
Oct-29-24 07:00AM
Oct-07-24 05:01PM
Sep-25-24 07:00AM
Sep-24-24 07:00AM
Aug-26-24 04:01PM
Aug-21-24 07:00AM
Aug-20-24 07:00AM
Aug-12-24 10:53PM
05:10PM
04:15PM
04:01PM
Jul-25-24 02:35AM
Jun-13-24 03:35PM
Jun-07-24 04:30PM
May-14-24 04:01PM
May-10-24 04:30PM
May-07-24 10:56PM
05:15PM
04:01PM
05:11AM
04:31AM
May-06-24 03:17PM
08:17AM
08:11AM
07:41AM
07:30AM
May-03-24 08:02AM
Mar-13-24 07:07AM
Mar-12-24 07:31AM
Mar-07-24 09:55AM
Mar-05-24 10:52PM
07:55AM
07:40AM
07:31AM
Feb-27-24 03:30AM
Jan-31-24 02:23PM
Jan-22-24 10:53AM
Jan-08-24 04:01PM
Dec-13-23 04:01PM
Dec-05-23 04:01PM
07:01AM
Nov-29-23 07:01AM
Nov-09-23 08:11AM
07:41AM
07:31AM
Oct-23-23 10:08AM
Oct-03-23 04:08PM
Sep-07-23 07:44AM
Aug-28-23 08:20AM
Aug-08-23 04:41PM
04:01PM
Jul-24-23 04:16PM
Jul-20-23 07:56AM
Jun-23-23 06:24AM
May-18-23 07:05AM
May-13-23 08:15AM
May-09-23 04:13PM
04:01PM
Apr-04-23 12:38PM
Mar-17-23 07:46AM
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.